Jazz Pharmaceuticals' Ziihera plus chemotherapy cuts death risk 24% in Phase 3 gastroesophageal cancer trial
Bitget2026/10/23 14:16- Jazz Pharmaceuticals presented updated Phase 3 Ziihera survival results in first-line HER2-positive advanced gastroesophageal adenocarcinoma at ESMO 2026.
- Ziihera with chemotherapy significantly improved overall survival versus trastuzumab with chemotherapy.
- Adding tislelizumab sustained survival benefits versus trastuzumab with chemotherapy, but did not significantly improve survival over Ziihera with chemotherapy.
- Safety profiles remained unchanged with longer follow-up.
- The FDA cleared both Ziihera regimens on August 25, 2026, for first-line treatment in specified HER2-positive patient groups.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.
AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).
Tom Lee Says Democratic Sweep Could Fuel 15% to 20% Tech Rally
Crypto prices
More
